1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-613.
2. Welch HG, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston: Random House; 2011.
3. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283:2975-2978.
4. Gotzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening: the facts: or maybe not. BMJ 2009;338:b86.
5. Bach PB. Is our natural-history model of lung cancer wrong? Lancet Oncol 2008;9:693-697.
6. Ahn HS, Welch HG. South Korea's thyroid-cancer “epidemic”: turning the tide. N Engl J Med 2015;373:2389-2390.
7. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med 1994;154:1838-1840.
8. Brito JP, Kim HJ, Han SJ, Lee YS, Ahn HS. Geographic distribution and evolution of thyroid cancer epidemic in South Korea. Thyroid 2016;26:864-865.
10. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
11. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid: a “normal” finding in Finland: a systematic autopsy study. Cancer 1985;56:531-538.
12. Chung JH. Prevalence of thyroid nodules detected by ultrasonography in adults for health check-up and analysis of fine needle aspiration cytology. J Korean Endocr Soc 2008;23:391-394.
13. Burke JP, Hay ID, Dignan F, Goellner JR, Achenbach SJ, Oberg AL, Melton LJ 3rd. Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999. Mayo Clin Proc 2005;80:753-758.
14. Kilfoy BA, Zhang Y, Park Y, Holford TR, Schatzkin A, Hollenbeck A, Ward MH. Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP diet and health Study. Int J Cancer 2011;129:160-172.
16. Almquist M, Johansen D, Bjorge T, Ulmer H, Lindkvist B, Stocks T, Hallmans G, Engeland A, Rapp K, Jonsson H, Selmer R, Diem G, Haggstrom C, Tretli S, Stattin P, Manjer J. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control 2011;22:743-751.
17. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ 2013;347:f4706.
18. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid 2013;23:449-455.
19. Montie JE, Wood DP Jr, Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989;63:381-385.
20. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-144.
21. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
23. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
25. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-1028.
26. Welch HG, Robertson DJ. Colorectal cancer on the decline: why screening can't explain it all. N Engl J Med 2016;374:1605-1607.